Biomarkers and Therapeutic Interventions for Cardiorenal Syndrome: A Literature Review.

Abstract

Acute or chronic cardiac and renal failure interact to worsen both organs' states in cardiorenal syndrome (CRS), a complicated medical disorder. This review covers biomarkers and therapeutic strategies in CRS management, highlighting current advancements and future prospects. A Scopus, Google Scholar, and PubMed search technique was used to examine relevant material from 2019-2024. Troponin and NT-proBNP are important cardiac biomarkers for CRS severity assessment, disease progression, and therapy options. Serum creatinine, cystatin C, and NGAL also reveal renal function and prognosis. In CRS, albuminuria, a measure of renal function and chronic kidney disease severity, is related to poor outcomes.Diuretics and ultrafiltration reduce fluid excess in CRS, while RAAS inhibitors increase survival and reverse cardiac remodeling in heart failure patients. SGLT2 inhibitors may protect the kidneys and heart. In certain cardiac diseases, non-pharmacological methods like ICDs and CRT may help. This review concludes with advancements in CRS biomarkers and treatment. Cardiac and renal biomarkers can predict CRS and SGLT2 inhibitors may improve CRS therapy. Research is required to improve these therapies and investigate other therapeutic ways to improve patient outcomes.

References

Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, et al. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. Circulation. 2019 Apr 16;139(16):E840–78.

Forman DE, Butler J, Wang Y, Abraham WT, O’Connor CM, Gottlieb SS, et al. Incidence, Predictors at Admission, and Impact of Worsening Renal Function among Patients Hospitalized with Heart Failure. J Am Coll Cardiol. 2004 Jan 7;43(1):61–7.

Santoro D, Gembillo G, Andò G. Glomerular filtration rate as a predictor of outcome in acute coronary syndrome complicated by atrial fibrillation. J Clin Med. 2020 May 1;9(5).

Virzì GM, Breglia A, Brocca A, De Cal M, Bolin C, Vescovo G, et al. Levels of Proinflammatory Cytokines, Oxidative Stress, and Tissue Damage Markers in Patients with Acute Heart Failure with and without Cardiorenal Syndrome Type 1. CardioRenal Med. 2018 Oct 1;8(4):321–31.

Lorin J, Guilland JC, Stamboul K, Guenancia C, Cottin Y, Rochette L, et al. Increased symmetric dimethylarginine level is associated with worse hospital outcomes through altered left ventricular ejection fraction in patients with acute myocardial infarction. PLoS One. 2017 Jan 1;12(1).

Tharaux PL. Histamine provides an original vista on cardiorenal syndrome. Proc Natl Acad Sci U S A. 2020 Mar 17;117(11):5550–2.

Xue JL, Daniels F, Star RA, Kimmel PL, Eggers PW, Molitoris BA, et al. Incidence and mortality of acute renal failure in Medicare beneficiaries, 1992 to 2001. J Am Soc Nephrol. 2006 Apr;17(4):1135–42.

Pimienta González R, Couto Comba P, Rodríguez Esteban M, Alemán Sánchez JJ, Hernández Afonso J, Rodríguez Pérez MDC, et al. Incidence, mortality and positive predictive value of type 1 cardiorenal syndrome in acute coronary syndrome. PLoS One. 2016 Dec 1;11(12).

Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, et al. Cardio-renal syndromes: Report from the consensus conference of the acute dialysis quality initiative. Eur Heart J. 2010 Mar;31(6):703–11.

Ceravolo G, La Macchia T, Cuppari C, Dipasquale V, Gambadauro A, Casto C, et al. Update on the classification and pathophysiological mechanisms of pediatric cardiorenal syndromes. Children. 2021 Jul 1;8(7).

Fishbein MC, Wang T, Matijasevic M, Hong L, Apple FS. Myocardial tissue troponins T and I: An immunohistochemical study in experimental models of myocardial ischemia. Cardiovasc Pathol. 2003;12(2):65–71.

Parikh RH, Seliger SL, deFilippi CR. Use and interpretation of high sensitivity cardiac troponins in patients with chronic kidney disease with and without acute myocardial infarction. Clin Biochem. 2015 Mar 1;48(4–5):247–53.

Bansal N, Zelnick LR, Ballantyne CM, Chaves PHM, Christenson RH, Coresh J, et al. Upper Reference Limits for High-Sensitivity Cardiac Troponin T and N-Terminal Fragment of the Prohormone Brain Natriuretic Peptide in Patients With CKD. Am J Kidney Dis. 2022 Mar 1;79(3):383–92.

Miller-Hodges E, Anand A, Shah ASV, Chapman AR, Gallacher P, Lee KK, et al. High-Sensitivity Cardiac Troponin and the Risk Stratification of Patients with Renal Impairment Presenting with Suspected Acute Coronary Syndrome. Circulation. 2018 Jan 30;137(5):425–35.

Alushi B, Jost-Brinkmann F, Kastrati A, Cassese S, Fusaro M, Stangl K, et al. High-sensitivity cardiac troponin t in patients with severe chronic kidney disease and suspected acute coronary syndrome. J Clin Med. 2021 Sep 1;10(18).

Ledwoch J, Krauth A, Kraxenberger J, Schneider A, Leidgschwendner K, Schneider V, et al. Accuracy of high-sensitive troponin depending on renal function for clinical outcome prediction in patients with acute heart failure. Heart Vessels. 2022 Jan 1;37(1):69–76.

He C, Liu J, Zhu Z, Pan H, Zheng Z, He J, et al. [Establishment and validation of a new predictive equation with multiple risk factors for the development of cardiorenal syndrome type 1 in patients with acute myocardial infarction]. Zhonghua Xin Xue Guan Bing Za Zhi [Internet]. 2021 Aug 24 [cited 2024 Apr 15];49(8):802–8. Available from: https://pubmed.ncbi.nlm.nih.gov/34404190/

McCallum W, Tighiouart H, Testani JM, Griffin M, Konstam MA, Udelson JE, et al. Association of Volume Overload With Kidney Function Outcomes Among Patients With Heart Failure With Reduced Ejection Fraction. Kidney Int Reports. 2020 Oct 1;5(10):1661–9.

de la Espriella R, Bayés-Genís A, Llàcer P, Palau P, Miñana G, Santas E, et al. Prognostic value of NT-proBNP and CA125 across glomerular filtration rate categories in acute heart failure. Eur J Intern Med. 2022 Jan 1;95:67–73.

Zhao HL, Hu HJ, Zhao XJ, Chi WW, Liu DM, Wang Q, et al. Urine N-terminal pro-B-type natriuretic peptide and plasma proenkephalin are promising biomarkers for early diagnosis of cardiorenal syndrome type 1 in acute decompensated heart failure: a prospective, double-center, observational study in real-world. Ren Fail. 2022;44(1):1486–97.

Nakashima M, Sakuragi S, Miyoshi T, Takayama S, Kawaguchi T, Kodera N, et al. Fibrosis-4 index reflects right ventricular function and prognosis in heart failure with preserved ejection fraction. ESC Hear Fail. 2021 Jun 1;8(3):2240–7.

Raimundo M, Crichton S, Martin JR, Syed Y, Varrier M, Wyncoll D, et al. Increased fluid administration after early acute kidney injury is associated with less renal recovery. Shock. 2015;44(5):431–7.

Niemantsverdriet MSA, Pieters TT, Hoefer IE, Verhaar MC, Joles JA, van Solinge WW, et al. GFR estimation is complicated by a high incidence of non-steady-state serum creatinine concentrations at the emergency department. PLoS One. 2021 Dec 1;16(12 December).

Phan Thai H, Hoang Bui B, Hoang Anh T, Huynh Van M. Value of Plasma NGAL and Creatinine on First Day of Admission in the Diagnosis of Cardiorenal Syndrome Type 1. Cardiol Res Pract. 2020;2020.

Delanaye P, Schaeffner E, Cozzolino M, Langlois M, Plebani M, Ozben T, et al. The new, race-free, Chronic Kidney Disease Epidemiology Consortium (CKD-EPI) equation to estimate glomerular filtration rate: Is it applicable in Europe? A position statement by the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM). Clin Chem Lab Med. 2023 Jan 1;61(1):44–7.

Chen S, Tang Y, Zhou X. Cystatin C for predicting all-cause mortality and rehospitalization in patients with heart failure: A meta-analysis. Biosci Rep. 2019 Feb 5;39(2).

Pinsino A, Mondellini GM, Royzman EA, Hoffman KL, D’Angelo D, Mabasa M, et al. Cystatin C- Versus Creatinine-Based Assessment of Renal Function and Prediction of Early Outcomes among Patients with a Left Ventricular Assist Device. Circ Hear Fail. 2020 Jan 1;13(1):E006326.

Zhang Y, Yang S, Chen J, Zhang Z, He P, Zhou C, et al. Associations of serum cystatin C and its change with new-onset cardiovascular disease in Chinese general population. Nutr Metab Cardiovasc Dis. 2022 Aug 1;32(8):1963–71.

Makris K, Rizos D, Kafkas N, Haliassos A. Neurophil gelatinase-associated lipocalin as a new biomarker in laboratory medicine. Clin Chem Lab Med. 2012 Sep 1;50(9):1519–32.

Mishra J, Qing MA, Prada A, Mitsnefes M, Zahedi K, Yang J, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol. 2003 Oct 1;14(10):2534–43.

Song X, Cai D, Zhang B. Clinical values of serum NGAL combined with NT-proBNP in the early prognosis of type 1 cardiorenal syndrome. Am J Transl Res [Internet]. 2021 [cited 2024 Apr 15];13(4):3363. Available from: /pmc/articles/PMC8129259/

Ferrari F, Scalzotto E, Esposito P, Samoni S, Mistrorigo F, Topete LMR, et al. Neutrophil gelatinase-associated lipocalin does not predict acute kidney injury in heart failure. World J Clin Cases. 2020 May 1;8(9):1600–7.

Nasonova SN, Zhirov I V., Ledyakhova M V., Sharf T V., Bosykh EG, Masenko VP, et al. Early diagnosis of acute renal injury in patients with acute decompensation of chronic heart failure. Ter Arkh. 2019;91(4):67–73.

Stevens PE, Levin A. Evaluation and management of chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013 Jun 4;158(11):825–30.

Funahashi Y, Ikeda M, Wakasaki R, Chowdhury S, Groat T, Zeppenfeld D, et al. Renal injury in cardiorenal syndrome type 1 is mediated by albumin. Physiol Rep. 2022 Feb 1;10(3).

LANDLER NE, OLSEN FJ, CHRISTENSEN J, BRO S, FELDT-RASMUSSEN BO, HANSEN D, et al. Associations Between Albuminuria, Estimated GFR and Cardiac Phenotype in a Cohort with Chronic Kidney Disease: The CPH-CKD ECHO Study. J Card Fail. 2022 Nov 1;28(11):1615–27.

Wang Y, Zhao X, Zhai M, Fan C, Huang Y, Zhou Q, et al. Elevated urinary albumin concentration predicts worse clinical outcomes in hospitalized acute decompensated heart failure patients. ESC Hear Fail. 2021 Aug 1;8(4):3037–48.

Kato T, Yaku H, Morimoto T, Inuzuka Y, Tamaki Y, Ozasa N, et al. Association of an increase in serum albumin levels with positive 1-year outcomes in acute decompensated heart failure: A cohort study. PLoS One. 2020 Dec 1;15(12 December).

Felker GM, Ellison DH, Mullens W, Cox ZL, Testani JM. Diuretic Therapy for Patients With Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol [Internet]. 2020 Mar 17 [cited 2024 Apr 15];75(10):1178–95. Available from: https://www.jacc.org/doi/10.1016/j.jacc.2019.12.059

Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers E, et al. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload. N Engl J Med [Internet]. 2022 Sep 29 [cited 2024 Apr 16];387(13):1185–95. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2203094

Wilcox CS, Testani JM, Pitt B. Pathophysiology of Diuretic Resistance and Its Implications for the Management of Chronic Heart Failure. Hypertension [Internet]. 2020 Oct 1 [cited 2024 Apr 16];76(4):1045–54. Available from: https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.120.15205

Lo KB, Rangaswami J. Mechanistic Insights in Cardiorenal Syndrome. NEJM Evid. 2022 Aug 23;1(9).

Rosenblum H, Kapur NK, Abraham WT, Udelson J, Itkin M, Uriel N, et al. Conceptual Considerations for Device-Based Therapy in Acute Decompensated Heart Failure: DRI2P2S. Circ Hear Fail. 2020 Apr 1;13(4).

Costanzo MR. Ultrafiltration in Acute Heart Failure. Card Fail Rev. 2019;5(1):9–18.

Bisht H, Tripathi A, Arya A, Konat A, Patel D, Godhani D, et al. Ultrafiltration in Heart Failure: A Review. Cureus. 2023 Jun 4;

Fudim M, Brooksbank J, Giczewska A, Greene SJ, Grodin JL, Martens P, et al. Ultrafiltration in acute heart failure: Implications of ejection fraction and early response to treatment from carress-hf. J Am Heart Assoc [Internet]. 2020 Dec 15 [cited 2024 Apr 16];9(24). Available from: https://www.ahajournals.org/doi/abs/10.1161/JAHA.119.015752

Lueder TG von, Kotecha D, Atar D, Hopper I. Neurohormonal Blockade in Heart Failure. Card Fail Rev [Internet]. 2017 [cited 2024 Apr 16];3(1):19. Available from: /pmc/articles/PMC5494151/

Savoia C, Battistoni A, Calvez V, Cesario V, Montefusco G, Filippini A. Microvascular Alterations in Hypertension and Vascular Aging. Curr Hypertens Rev. 2017 May 9;13(1).

Bhandari S, Mehta S, Khwaja A, Cleland JGF, Ives N, Brettell E, et al. Renin–Angiotensin System Inhibition in Advanced Chronic Kidney Disease. N Engl J Med [Internet]. 2022 Dec 1 [cited 2024 Apr 16];387(22):2021–32. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2210639

Weir MR, Lakkis JI, Jaar B, Rocco M V., Choi MJ, Kramer HJ, et al. Use of Renin-Angiotensin System Blockade in Advanced CKD: An NKF-KDOQI Controversies Report. Am J Kidney Dis. 2018 Dec 1;72(6):873–84.

McCallum W, Tighiouart H, Ku E, Salem D, Sarnak MJ. Trends in Kidney Function Outcomes Following RAAS Inhibition in Patients With Heart Failure With Reduced Ejection Fraction. Am J Kidney Dis. 2020 Jan 1;75(1):21–9.

Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, et al. Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med [Internet]. 2019 Feb 7 [cited 2024 Apr 16];380(6):539–48. Available from: https://www.nejm.org/doi/full/10.1056/nejmoa1812851

Damman K, Gori M, Claggett B, Jhund PS, Senni M, Lefkowitz MP, et al. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. JACC Hear Fail [Internet]. 2018 Jun 1 [cited 2024 Apr 16];6(6):489–98. Available from: https://www.jacc.org/doi/10.1016/j.jchf.2018.02.004

Spannella F, Giulietti F, Filipponi A, Sarzani R. Effect of sacubitril/valsartan on renal function: a systematic review and meta-analysis of randomized controlled trials. ESC Hear Fail [Internet]. 2020 Dec 1 [cited 2024 Apr 16];7(6):3487–96. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/ehf2.13002

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med [Internet]. 2019 Jan 24 [cited 2024 Apr 16];380(4):347–57. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa1812389

Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet [Internet]. 2019 Jan 5 [cited 2024 Apr 16];393(10166):31–9. Available from: http://www.thelancet.com/article/S014067361832590X/fulltext

Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet [Internet]. 2022 Sep 3 [cited 2024 Apr 16];400(10354):757–67. Available from: http://www.thelancet.com/article/S0140673622014295/fulltext

Zelniker TA, Braunwald E. Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. J Am Coll Cardiol [Internet]. 2020 Feb 4 [cited 2024 Apr 16];75(4):422–34. Available from: https://www.jacc.org/doi/10.1016/j.jacc.2019.11.031

Wheeler DC, Stefánsson B V., Jongs N, Chertow GM, Greene T, Hou FF, et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol [Internet]. 2021 Jan 1 [cited 2024 Apr 16];9(1):22–31. Available from: http://www.thelancet.com/article/S2213858720303697/fulltext

Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol [Internet]. 2019 Nov 1 [cited 2024 Apr 16];7(11):845–54. Available from: http://www.thelancet.com/article/S2213858719302566/fulltext

Wang A, Li Z, Zhuo S, Gao F, Zhang H, Zhang Z, et al. Mechanisms of Cardiorenal Protection With SGLT2 Inhibitors in Patients With T2DM Based on Network Pharmacology. Front Cardiovasc Med. 2022 May 23;9:857952.

Monzo L, Ferrari I, Cicogna F, Tota C, Calò L. What proportion of patients with heart failure and preserved ejection fraction are eligible for empagliflozin? J Cardiovasc Med [Internet]. 2022 Aug 1 [cited 2024 Apr 16];23(8):567–9. Available from: https://journals.lww.com/jcardiovascularmedicine/fulltext/2022/08000/what_proportion_of_patients_with_heart_failure_and.12.aspx

Monzo L, Ferrari I, Cicogna F, Tota C, Calò L. Sodium–glucose co-transporter-2 inhibitors eligibility in patients with heart failure with reduced ejection fraction. Int J Cardiol. 2021 Oct 15;341:56–9.

Salvatore T, Galiero R, Caturano A, Rinaldi L, Di Martino A, Albanese G, et al. An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors. Int J Mol Sci 2022, Vol 23, Page 3651 [Internet]. 2022 Mar 26 [cited 2024 Apr 16];23(7):3651. Available from: https://www.mdpi.com/1422-0067/23/7/3651/htm

Li L, Konishi Y, Morikawa T, Zhang Y, Kitabayashi C, Kobara H, et al. Effect of a SGLT2 inhibitor on the systemic and intrarenal renin–angiotensin system in subtotally nephrectomized rats. J Pharmacol Sci. 2018 Jun 1;137(2):220–3.

van Raalte DH, Bjornstad P. Role of sodium-glucose cotransporter 2 inhibition to mitigate diabetic kidney disease risk in type 1 diabetes. Nephrol Dial Transplant [Internet]. 2020 Jan 1 [cited 2024 Apr 16];35(Supplement_1):i24–32. Available from: https://dx.doi.org/10.1093/ndt/gfz228

McDonagh TA, Metra M, Adamo M, Baumbach A, Böhm M, Burri H, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J [Internet]. 2021 Sep 21 [cited 2024 Apr 15];42(36):3599–726. Available from: https://dx.doi.org/10.1093/eurheartj/ehab368

Edwards NC, Group BC-R, Price AM, Group BC-R, Steeds RP, Group BC-R, et al. Management of heart failure in patients with kidney disease—updates from the 2021 ESC guidelines. Nephrol Dial Transplant [Internet]. 2023 Jul 31 [cited 2024 Apr 16];38(8):1798–806. Available from: https://dx.doi.org/10.1093/ndt/gfad011

Kiage JN, Latif Z, Craig MA, Mansour N, Khouzam RN. Implantable Cardioverter Defibrillators and Chronic Kidney Disease. Curr Probl Cardiol. 2021 Mar 1;46(3):100639.

Wouter Jukema J, Timal RJ, Rotmans JI, Hensen LCR, Buiten MS, De Bie MK, et al. Prophylactic Use of Implantable Cardioverter-Defibrillators in the Prevention of Sudden Cardiac Death in Dialysis Patients. Circulation [Internet]. 2019 Jun 4 [cited 2024 Apr 16];139(23):2628–38. Available from: https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.119.039818